Categories: News

Bemax Inc. Launches Discount Bulk Purchasers’ Program

  • Bulk purchaser’s discount is a follow up to Bemax buying agents discount program
  • Buying agents added over one million dollars to sales last quarter.

Dallas, Georgia–(Newsfile Corp. – December 3, 2024) – Bemax Inc. (OTC Pink: BMXC), a private label development company with a focus on disposable diapers and women’s hygienic sanitary products, is pleased to announce its new discount bulk purchase program for wholesale and retail distribution of the new, improved quality Mother’s Touch® brand of disposable diapers.

The buying agent discount program, which initially began during the last fiscal quarter, has brought in over one million dollars in sales. Bemax has begun to leverage the distribution strength that buying agents bring while offering bulk purchasers exclusive distribution rights.

This strategic move is part of our ongoing commitment to expanding our global distribution network, delivering immediate financial benefit through more profits to our bulk purchasers and consistent growth of our revenue.

“At Bemax, the introduction of a discount purchase program is a testament to our continued commitment to expand our distribution network and our dedication to our customers,” says Taiwo Aimasiko, CEO, Bemax Inc. “We are excited to deliver more returns to our customers, enhance the quality of our distribution across all our sales platforms, and continue to drive our revenue growth.”

About Bemax Inc.
Bemax Inc. is a forward-thinking company dedicated to delivering top-quality disposable diapers and women’s hygienic sanitary products. With a focus on innovation and customer satisfaction, Bemax continues to expand its product offerings and distribution network, aiming to exceed the expectations of its growing customer base. Bemax Inc. exports and distribute private label household products to the global emerging markets. www.bemaxinc.com.

Safe Harbor Statement
This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results or implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company’s control. Forward-Looking statements speak only as to the date they are made and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

CONTACT INFORMATION
Bemax Inc.
Dallas, GA
USA
Taiwo Aimasiko
Email: admin@bemaxinc.com
Tel: (470) 582 0807 ext. 101

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232289

Staff

Recent Posts

TestoPrime Review: Why TestoPrime Is Better Than Other Testosterone Booster Supplement in 2025?

TestoPrime is a top rated, all natural testosterone booster for men in their 40's and…

55 minutes ago

Lipozem Reviews: Does It Really Work For Weight Loss in 2025?

Lipozem: We Tested Lipozem Supplement - Here Is Our Honest Review NEW YORK CITY, NY…

55 minutes ago

Assessing Post-Cardiac Surgery Kidney Recovery Through PenKid’s Emerging Role in Renal Replacement Therapy Decisions

Proenkephalin A 119-159 (penKid) demonstrates potential as a predictor for successful discontinuation of continuous renal…

55 minutes ago

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7…

5 hours ago

RiDYMO® Designs Cyclic Peptide for “Undruggable” β-Catenin Target Within Two Months

BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has…

7 hours ago